A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia

Trial Profile

A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Aug 2018

At a glance

  • Drugs Moxetumomab pasudotox (Primary)
  • Indications Hairy cell leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 01 Aug 2018 Trial has been completed in Czech Republic.
    • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association.
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top